Celldex Therapeutics (CLDX) has moved back into focus after completing enrollment ahead of schedule for its large Phase 3 barzolvolimab trials in chronic spontaneous urticaria and sharing new long term Phase 2 data at AAAAI.

The recent completion of Phase 3 enrollment and fresh AAAAI data arrive after a sharp 30.71% 7 day share price return, building on an 11.40% year to date share price gain and a 46.28% 1 year total shareholder return, even though the 3 year total shareholder return remains negative.

If Celldex’s progress has you looking across biotech, this could be a handy moment to scan our screener of 27 healthcare AI stocks for other potential ideas in the space.

With the share price already up sharply and analysts’ targets sitting well above the latest close, the real question is whether Celldex is still trading at a discount or whether the market is already pricing in future growth.

Preferred Price to Book of 3.8x: Is it justified?

Celldex trades on a P/B of 3.8x, and with the last close at $30.09, that sits between its peers and the level our models suggest.

P/B compares the company’s market value to its net assets, which matters for early stage biopharma names like Celldex where earnings are still negative and revenue is limited.

At 3.8x, Celldex is described as good value relative to a peer average of 8.1x. It screens as expensive against the broader US biotech industry average of 2.7x. That split signals investors are paying more than the industry overall for Celldex’s asset base, but less than for a closer peer set that the market currently prices at a richer level. Our SWS DCF model separately flags a very large gap between the share price and its projected future cash flow value of $208.73 per share.

Result: Price to Book Ratio of 3.8x (ABOUT RIGHT)

However, you also need to factor in execution risks around Celldex’s clinical programs and the company’s current net loss of $258.757 million on very limited revenue.

Another View, What Our DCF Model Is Saying

If you set the P/B to one side and look at cash flows instead, our SWS DCF model points to a future cash flow value of $208.73 per share, compared with the current $30.09 price. That gap suggests the market is either very cautious or the model is too optimistic. The question for investors is which one they find more convincing.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of upside potential and clinical risk feels finely balanced, it may be worth acting sooner rather than later and weighing the 2 key rewards and 2 important warning signs alongside your own research.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. Use focused screens to surface other ideas that fit your approach.

• Target higher potential returns by scanning screener containing 24 high quality undiscovered gems that our filters highlight for quality and under the radar fundamentals.
• Strengthen your income stream by reviewing 15 dividend fortresses that meet strict yield and resilience criteria.
• Lower portfolio stress by checking 76 resilient stocks with low risk scores selected for more resilient risk profiles and balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.